All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic

Objective To investigate all-cause mortality, COVID-19 mortality and all-cause non-COVID-19 mortality in Qatar during the COVID-19 pandemic. Methods A national, retrospective cohort analysis and national, matched, retrospective cohort studies were conducted between 5 February 2020 and 19 September 2022. Results There were 5025 deaths during a follow-up time of 5 247 220 person-years, of which 675 were COVID-19 related. Incidence rates were 0.96 (95% CI 0.93 to 0.98) per 1000 person-years for all-cause mortality, 0.13 (95% CI 0.12 to 0.14) per 1000 person-years for COVID-19 mortality and 0.83 (95% CI 0.80 to 0.85) per 1000 person-years for all-cause non-COVID-19 mortality. Adjusted HR, comparing all-cause non-COVID-19 mortality relative to Qataris, was lowest for Indians at 0.38 (95% CI 0.32 to 0.44), highest for Filipinos at 0.56 (95% CI 0.45 to 0.69) and was 0.51 (95% CI 0.45 to 0.58) for craft and manual workers (CMWs). Adjusted HR, comparing COVID-19 mortality relative to Qataris, was lowest for Indians at 1.54 (95% CI 0.97 to 2.44), highest for Nepalese at 5.34 (95% CI 1.56 to 18.34) and was 1.86 (95% CI 1.32 to 2.60) for CMWs. Incidence rate of all-cause mortality for each nationality group was lower than the crude death rate in the country of origin. Conclusions Risk of non-COVID-19 death was low and was lowest among CMWs, perhaps reflecting the healthy worker effect. Risk of COVID-19 death was also low, but was highest among CMWs, largely reflecting higher exposure during first epidemic wave, before advent of effective COVID-19 treatments and vaccines.

[1]  Gheyath K Nasrallah,et al.  Protection against Reinfection with the Omicron BA.2.75 Subvariant , 2023, The New England journal of medicine.

[2]  Gheyath K Nasrallah,et al.  Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study , 2022, The Lancet Infectious Diseases.

[3]  Gheyath K Nasrallah,et al.  Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants , 2022, The New England journal of medicine.

[4]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[5]  L. Abu-Raddad,et al.  Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar , 2022, International Journal of Infectious Diseases.

[6]  L. Abu-Raddad,et al.  Type 2 diabetes epidemic and key risk factors in Qatar: a mathematical modeling analysis , 2022, BMJ Open Diabetes Research & Care.

[7]  Gheyath K Nasrallah,et al.  Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.

[8]  Gheyath K Nasrallah,et al.  Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.

[9]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[10]  L. Abu-Raddad,et al.  Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.

[11]  Gheyath K Nasrallah,et al.  Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study , 2021, PLoS medicine.

[12]  L. Abu-Raddad,et al.  BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.

[13]  L. Abu-Raddad,et al.  Characterizing epidemiology of prediabetes, diabetes, and hypertension in Qataris: A cross-sectional study , 2021, PloS one.

[14]  L. Abu-Raddad,et al.  SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.

[15]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[16]  Gheyath K Nasrallah,et al.  SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.

[17]  L. Abu-Raddad,et al.  Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.

[18]  Gheyath K Nasrallah,et al.  SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy , 2021, EClinicalMedicine.

[19]  Gheyath K Nasrallah,et al.  COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar , 2021, medRxiv.

[20]  J. Tuomilehto,et al.  A diabetes risk score for Qatar utilizing a novel mathematical modeling approach to identify individuals at high risk for diabetes , 2021, Scientific Reports.

[21]  Gheyath K Nasrallah,et al.  SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals , 2021, iScience.

[22]  R. Bertollini,et al.  Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 , 2020, medRxiv.

[23]  L. Abu-Raddad,et al.  Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020 , 2020, BMJ Open.

[24]  R. Irizarry,et al.  Every Body Counts: Measuring Mortality From the COVID-19 Pandemic , 2020, Annals of Internal Medicine.

[25]  R. Bertollini,et al.  Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.

[26]  L. Abu-Raddad,et al.  Preventing type 2 diabetes mellitus in Qatar by reducing obesity, smoking, and physical inactivity: mathematical modeling analyses , 2019, Population Health Metrics.

[27]  A. El-Menyar,et al.  Epidemiological and clinical characteristics of fall-related injuries: a retrospective study , 2019, BMC Public Health.

[28]  D. Atar,et al.  Heat Stress Impacts on Cardiac Mortality in Nepali Migrant Workers in Qatar , 2019, Cardiology.

[29]  R. Latifi,et al.  Predictors and Time-Based Hospital Mortality in Patients with Isolated and Polytrauma Brain Injuries , 2018, World Journal of Surgery.

[30]  Martin O'Flaherty,et al.  Forecasting the burden of type 2 diabetes mellitus in Qatar to 2050: A novel modeling approach. , 2017, Diabetes research and clinical practice.

[31]  R. Mamtani,et al.  Migrants, healthy worker effect, and mortality trends in the Gulf Cooperation Council countries , 2017, PloS one.

[32]  A. Hyder,et al.  Epidemiology of occupational injuries by nationality in Qatar: Evidence for focused occupational safety programmes. , 2015, Injury.

[33]  E. Sadoun,et al.  Change in the structures, dynamics and disease-related mortality rates of the population of Qatari nationals: 2007–2011 , 2013, Journal of epidemiology and global health.

[34]  A. Ghaffar,et al.  Trends in childhood trauma mortality in the fast economically developing State of Qatar , 2011, World journal of pediatrics : WJP.

[35]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[36]  Abdulbari Bener,et al.  The neglected epidemic: Road traffic accidents in a developing country, State of Qatar , 2005, International journal of injury control and safety promotion.

[37]  C. Y. Li,et al.  A review of the healthy worker effect in occupational epidemiology. , 1999, Occupational medicine.

[38]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .